PARP inhibitor rucaparib in combination with imipridones ONC201 or ONC212 demonstrates preclinical synergy against BRCA1/2-deficient breast, ovarian, and prostate cancer cells

被引：0
|
作者：
Ghandali, Maryam
Huntington, Kelsey E.
Srinivasan, Praveen
Dizon, Don S.
Graff, Stephanie L.
Carneiro, Benedito A.
El-Deiry, Wafik S.
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-1066
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1066
引用
收藏
页数：2
相关论文
共 7 条
  • [1] ONC201 shows efficacy in BRCA-deficient cancer cells and synergy with PARP inhibitors in glioblastoma, breast, prostate, and ovarian cancers
    Baumeister, Marie D.
    Kucukkase, Ozan C.
    Prabhu, Varun V.
    Dicker, David T.
    Allen, Josh E.
    El-Deiry, Wafik S.
    CANCER RESEARCH, 2017, 77
  • [2] Anti-cancer efficacy of imipridones in pancreatic cancer: single agent ONC212 or combination of ONC201 with IGF1-R inhibition
    Lev, Avital
    Lulla, Amriti R.
    Wagner, Jessica
    Dicker, David T.
    El-Deiry, Wafik S.
    CANCER RESEARCH, 2017, 77
  • [3] Neuroendocrine prostate cancer drivers SOX2 and BRN2 confer differential responses to imipridones ONC201, ONC206, and ONC212 in prostate cancer cell lines
    Purcell, Connor
    Srinivasan, Praveen R.
    Pinho-Schwermann, Maximilian
    Macdonald, William J.
    Ding, Elizabeth
    El-Deiry, Wafik S.
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2024, 16 (12): : 7972 - 7982
  • [4] ONC201 induces cell death in triple negative, BRCA1-deficient and non-triple negative breast cancer cells
    Baumeister, Marie A.
    Wagner, Jessica
    Prabhu, Varun V.
    Kline, Christina L. B.
    Lim, Bora
    Allen, Josh E.
    Dicker, David T.
    El-Deiry, Wafik S.
    CANCER RESEARCH, 2016, 76
  • [5] Preclinical activity of new investigational drug ONC201 in triple-negative and non-triple negative and BRCA1-deficient breast cancer cells.
    Baumeister, Marie D.
    Wagner, Jessica
    Prabhu, Varun V.
    Kline, Christina Leah B.
    Allen, Joshua E.
    Dicker, David T.
    El-Deiry, Wafik S.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [6] Preclinical evaluation of the PARP inhibitor rucaparib in combination with PD-1 and PD-L1 inhibition in a syngeneic BRCA1 mutant ovarian cancer model
    Robillard, Liliane
    Nguyen, Minh
    Loehr, Andrea
    Orsulic, Sandra
    Kristeleit, Rebecca S.
    Lin, Kevin
    Raponi, Mitch
    Harding, Thomas C.
    Simmons, Andrew D.
    CANCER RESEARCH, 2017, 77
  • [7] Phase I study of the PARP inhibitor olaparib (O) in combination with carboplatin (C) in BRCA1/2 mutation carriers with breast (Br) or ovarian (Ov) cancer (Ca).
    Lee, J.
    Annunziata, C. M.
    Minasian, L. M.
    Zujewski, J.
    Prindiville, S. A.
    Kotz, H. L.
    Squires, J.
    Houston, N. D.
    Ji, J. J.
    Yu, M.
    Doroshow, J. H.
    Kohn, E. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
1